Tirzepatide demonstrated a lower risk of the secondary composite endpoint in heart failure hospitalization, urgent heart failure visit or all-cause mortality compared to dulaglutide HR 0.75 (95% CI 0.65 to 0.86)
For Ozempic, this typically starts at 0.25 mg once weekly for 4 weeks, then increasing to 0.5 mg, with further increases as needed
Those usually subsided, but led about 5% of study participants to stop taking it
Sustainable fat loss is one outcome, but the programme primarily targets metabolic health markers (HbA1c, fasting insulin, lipid profile, liver enzymes, blood pressure) and longevity indicators (visceral fat, sarcopenic muscle preservation, cardiovascular risk)
As Stephen ORahilly, an endocrinologist and director of the University of Cambridge MRC Metabolic Diseases Unit, pointed out, obesity is also associated with poor fetal outcomes, heightening a womans risk of everything from stillbirth to diabetes and high blood pressure